Unknown PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT03033368

Rilpivirine in Virologically Suppressed Adolescents

Treatment Switch From Efavirenz to Rilpivirine in Virologically-suppressed HIV-infected Thai Adolescents

Sponsor: Mahidol University

Conditions HIV

Interventions Rilpivirine

Updated 6 times since 2017 Last updated: Jan 24, 2017 Started: Jul 31, 2015 Primary completion: Jun 30, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03033368, this PHASE2/PHASE3 trial focuses on HIV and remains ongoing. Sponsored by Mahidol University, it has been updated 6 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Feb 2019 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

Status: Enrolling By Invitation → Unknown Status
Jun 2018 — Feb 2019 [monthly]

Enrolling By Invitation PHASE2_PHASE3

▶ Show 1 earlier version

Feb 2017 — Jun 2018 [monthly]

Enrolling By Invitation PHASE2_PHASE3

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mahidol University
amfAR, The Foundation for AIDS Research

Data source: Mahidol University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.